UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 3.294

Sortiert nach

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954

Biochemical pharmacology, 2010-03, Vol.79 (5), p.678-687

2010

Volltextzugriff (PDF)

uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954

Journal of biotechnology, 2010-10, Vol.150 (1), p.190-194

2010

Volltextzugriff (PDF)

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT

British journal of cancer, 2004-03, Vol.90 (5), p.1084-1092

2004

Volltextzugriff (PDF)

Novel chimeric gene promoters responsive to hypoxia and ionizing radiation

Gene therapy, 2002-10, Vol.9 (20), p.1403-1411

2002

Volltextzugriff (PDF)

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

Gene therapy, 2002-07, Vol.9 (14), p.946-954

2002

Volltextzugriff (PDF)

Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs

Protein engineering, design and selection, 2014-10, Vol.27 (10), p.399-403

2014

Volltextzugriff (PDF)

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069

British journal of cancer, 1997-11, Vol.76 (10), p.1338-1347

1997

Volltextzugriff (PDF)

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase

British journal of cancer, 1995-09, Vol.72 (3), p.669-675

1995

Volltextzugriff (PDF)

Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954

Biochemical pharmacology, 2012-09, Vol.84 (6), p.775-783

2012

Volltextzugriff (PDF)

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

British journal of cancer, 2000-02, Vol.82 (3), p.651-656

2000

Volltextzugriff (PDF)

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)

British journal of cancer, 1995-11, Vol.72 (5), p.1144-1150

1995

Volltextzugriff (PDF)

The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines

Anti-cancer drugs, 2004-01, Vol.15 (1), p.71-77

2004

Volltextzugriff (PDF)

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha

British journal of cancer, 2000-07, Vol.83 (2), p.219-224

2000

Volltextzugriff (PDF)

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411

Cancer gene therapy, 2007-12, Vol.14 (12), p.953-967

2007

Volltextzugriff (PDF)

Targeting gene expression to hypoxic tumor cells

Nature medicine, 1997-05, Vol.3 (5), p.515-520

1997

Volltextzugriff (PDF)

Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation

Radiotherapy and oncology, 2004-03, Vol.70 (3), p.311-317

2004

Volltextzugriff (PDF)

Enzymology of tirapazamine metabolism: a review

Anti-cancer drug design, 1998-09, Vol.13 (6), p.541

1998

Volltextzugriff (PDF)

Prodrugs in genetic chemoradiotherapy

Current pharmaceutical design, 2003-10, Vol.9 (26), p.2131

2003

Volltextzugriff (PDF)

Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro

Cancer research (Chicago, Ill.), 1998-07, Vol.58 (13), p.2737-2740

1998

Volltextzugriff (PDF)

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233)

International journal of radiation oncology, biology, physics, 1994-05, Vol.29 (2), p.369-372

1994

Volltextzugriff (PDF)

Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours

Current pharmaceutical design, 2002-01, Vol.8 (15), p.1319

2002

Volltextzugriff (PDF)

The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions

Biochemical pharmacology, 2000-04, Vol.59 (8), p.993-996

2000

Volltextzugriff (PDF)

Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards

Radiation research, 2007-06, Vol.167 (6), p.625-636

2007

Volltextzugriff (PDF)

Can Gene Therapy Overcome the Problem of Hypoxia in Radiotherapy?

JOURNAL OF RADIATION RESEARCH, 2000, Vol.41 (3), p.201-212

2000

Volltextzugriff (PDF)

Synthesis and Structure−Activity Relationships for 2,4-Dinitrobenzamide-5-mustards as Prodrugs for the Escherichia coli nfsB Nitroreductase in Gene Therapy

Journal of medicinal chemistry, 2007-03, Vol.50 (6), p.1197-1212

2007

Volltextzugriff (PDF)

1 – 25 von 3.294

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.764)
Mit Volltextzugriff
(2.853)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.966)
Life Sciences & Biomedicine
(1.483)
Humans
(1.181)
Female
(617)
Male
(590)
Biological And Medical Sciences
(557)
Medical Sciences
(430)
Physical Sciences
(400)
Middle Aged
(375)
Adult
(357)
Animals
(355)
Aged
(273)
Physics
(199)
Technology
(189)
Chemistry
(158)
Fundamental And Applied Biological Sciences. Psychology
(146)
Adolescent
(140)
Psychiatry
(138)
Neurosciences & Neurology
(135)
Exact Sciences And Technology
(125)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954

uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT

Novel chimeric gene promoters responsive to hypoxia and ionizing radiation

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase

Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)

The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411

Targeting gene expression to hypoxic tumor cells

Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation

Enzymology of tirapazamine metabolism: a review

Prodrugs in genetic chemoradiotherapy

Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233)

Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours

The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions

Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards

Can Gene Therapy Overcome the Problem of Hypoxia in Radiotherapy?

Synthesis and Structure−Activity Relationships for 2,4-Dinitrobenzamide-5-mustards as Prodrugs for the Escherichia coli nfsB Nitroreductase in Gene Therapy

Suchergebnisse filtern